
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)11984-6
10.1016/j.heliyon.2024.e35953
e35953
Research Article
A systematic review and meta-analysis of ischemia-modified albumin in diabetes mellitus
Zinellu Angelo a
Mangoni Arduino A. arduino.mangoni@flinders.edu.au
bc⁎
a Department of Biomedical Sciences, University of Sassari, Sassari, Italy
b Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, Australia
c Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia
⁎ Corresponding author. Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Bedford Park, SA, 5042, Australia. arduino.mangoni@flinders.edu.au
10 8 2024
30 8 2024
10 8 2024
10 16 e3595314 2 2024
2 8 2024
6 8 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Aim

There is an ongoing search for novel biomarkers of diabetes. We conducted a systematic review and meta-analysis of the serum concentrations of ischemia-modified albumin (IMA), a candidate biomarker of oxidative stress, acidosis, and ischemia, in patients with pre-diabetes, different types of diabetes mellitus (type 1, T1DM, type 2, T2DM, and gestational, GDM), and healthy controls.

Methods

We searched for case-control studies published in PubMed, Web of Science, and Scopus from inception to December 31, 2023. The risk of bias and the certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and GRADE, respectively.

Results

In 29 studies, T2DM patients had significantly higher IMA concentrations when compared to controls (standard mean difference, SMD = 1.83, 95 % CI 1.46 to 2.21, p˂0.001; I2 = 95.7 %, p < 0.001; low certainty of evidence). Significant associations were observed between the SMD and glycated hemoglobin (p = 0.007), creatinine (p = 0.003), triglycerides (p = 0.029), and the presence of diabetes complications (p = 0.003). Similar trends, albeit in a smaller number of studies, were observed in T1DM (two studies; SMD = 1.59, 95 % CI -0.09 to 3.26, p˂0.063; I2 = 95.8 %, p < 0.001), GDM (three studies; SMD = 3.41, 95 % CI 1.14 to 5.67, p = 0.003; I2 = 97.0 %, p < 0.001) and pre-diabetes (three studies; SMD = 15.25, 95 % CI 9.86 to 20.65, p˂0.001; I2 = 99.3 %, p < 0.001).

Conclusion

Our study suggests that IMA is a promising biomarker for determining the presence of oxidative stress, acidosis, and ischemia in pre-diabetes and T1DM, T2DM, and GDM. However, the utility of measuring circulating IMA warrants confirmation in prospective studies investigating clinical endpoints in pre-diabetes and in different types of diabetes (PROSPERO registration number: CRD42024504690).

Highlights

• T2DM patients had significantly higher IMA concentrations than controls.

• Similar trends were observed in T1DM, GDM, and pre-diabetes.

• IMA is a promising biomarker of pre-diabetes and T1DM, T2DM, and GDM.

Keywords

Ischemia-modified albumin
IMA
Type 1 diabetes
Type 2 diabetes
Gestational diabetes
Pre-diabetes
Biomarkers
==== Body
pmc1 Introduction

Diabetes mellitus, particularly type 2 (T2DM), remains a global public health burden [1,2]. In 2021, T2DM accounted for 96 % of total cases of diabetes (529 million people living with diabetes worldwide) and 95.4 % of disability-adjusted life years due to diabetes. It is estimated that more than 1.31 billion people will have diabetes by 2050 [3]. Despite these figures undisputedly support the notion that T2DM represents the bulk of the cases of diabetes and their associated negative impact on quality of life and burden on healthcare systems, the global and/or local incidence of other types of diabetes mellitus, particularly type 1 (T1DM) and gestational (GDM), as well as pre-diabetes also continues to grow at an alarming rate [[4], [5], [6], [7], [8], [9], [10], [11]].

While the increasing availability of safe and effective hypoglycemic agents and insulins has revolutionized the management of different types of diabetes [[12], [13], [14], [15], [16], [17], [18]], a significant body of research has increasingly focused on the identification of robust disease biomarkers to enhance early diagnosis and risk stratification and predict response to therapy and clinical outcomes [19]. Circulating, e.g., glycated hemoglobin [20], and imaging, e.g., left ventricular global longitudinal strain on echocardiography [21], biomarkers are available in clinical practice. Other biomarkers, e.g., adiponectin, fetuin A, alpha-hydroxybutyrate, C-reactive protein (CRP), interleukin-6, white blood cell count, and fibrinogen have also been investigated with mixed results [[22], [23], [24]]. In addition to glycation, albumin, one of the most abundant circulating proteins, can also undergo a series of chemical modifications targeting the N-terminal sequence in the presence of ischemic conditions, which lead to the formation of ischemia-modified albumin (IMA) [25]. It has been suggested that these chemical modifications are triggered by oxidative stress, increased production of reactive oxygen species, and acidosis, which are typically associated with ischaemic events. Notably, such modifications reduce the binding capacity of IMA for metals, particularly copper, nickel, and cobalt [25]. Serum concentrations of IMA have been shown to increase within 24 h of the occurrence of an acute ischemic stroke and gradually decrease over the following days [26]. Similarly, several other studies have investigated the pathophysiological role of IMA in conditions of cardiac ischemia [[27], [28], [29]]. Given that the formation of IMA reflects, in addition to ischemia, the presence of oxidative stress and acidosis, common alterations observed in patients with diabetes [[30], [31], [32], [33], [34]], we conducted a systematic review and meta-analysis of serum IMA concentrations in patients with pre-diabetes, TD2M, TD1M, and GDM, and in healthy controls. We hypothesised that patients with pre-diabetes and diabetes have significantly higher concentrations of serum IMA compared to healthy controls, highlighting the potential role of IMA as a biomarker of diabetes.

2 Materials and methods

2.1 Search strategy and study selection

We conducted a systematic search for articles published in PubMed, Web of Science, and Scopus from inception to December 31, 2023 using the following terms: “IMA” OR “ischemia modified albumin” OR “ischemia-modified albumin” AND “diabetes”. Two investigators independently screened each abstract and, if relevant, the full text of the publication according to the following inclusion criteria: (i) measurement of serum IMA, (ii) comparison of patients with diabetes (type 1 diabetes mellitus, T1DM, type 2 diabetes mellitus, T2DM, gestational diabetes mellitus, GDM, or pre-diabetes) and healthy controls in case-control studies, (iii) use of English language, and (iv) availability of the full-text of the publication. The references of individual articles were hand-searched for additional studies.

The following variables were independently extracted and transferred into an electronic spreadsheet for further analysis: year of publication, first author, study country, type of diabetes, sample size, age, male to female ratio, mean disease duration, body mass index (BMI), C-reactive protein (CRP), glucose, glycated hemoglobin, albumin, creatinine, cholesterol (total, LDL and HDL), triglycerides, systolic and diastolic pressure, and presence of diabetic complications (e.g., diabetic retinopathy, neuropathy, nephropathy, diabetic foot, cardiovascular disease, and albuminuria) [35].

We calculated the risk of bias and the certainty of evidence using established methods [36,37] and used the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement to accurately report the relevant methods for identifying, selecting, appraising, and synthesizing studies (Supplementary Tables 1 and 2) [38]. We registered the study protocol in an international registry (PROSPERO registration number CRD42024504690).

2.2 Statistical analysis

We calculated standardized mean differences (SMDs) and 95 % confidence intervals (CIs) to generate forest plots to investigate differences in serum IMA concentrations between patients with diabetes and healthy controls (a p-value <0.05 was considered statistically significant). If required, means and standard deviations were extrapolated from medians and interquartile ranges or medians and ranges according to published methods [39]. SMD heterogeneity was assessed using the Q statistic (significance level at p < 0.10) and was interpreted as low when I2 ≤ 25 %, moderate when 25 % < I2 < 75 %, and high when I2 ≥ 75 % [40,41]. High heterogeneity warranted the use of random-effect models based on the inverse-variance method.

Sensitivity analysis was performed to confirm the stability of the meta-analysis results [42]. The presence of publication bias was assessed using the Begg's and the Egger's test and the “trim and fill” method [[43], [44], [45]].

Univariate meta-regression analyses were conducted to investigate associations between the effect size and year of publication, study country, sample size, age, male-to-female ratio, mean disease duration, BMI, CRP, glucose, glycated hemoglobin, albumin, creatinine, cholesterol (total, LDL and HDL), triglycerides, systolic and diastolic pressure, and presence of complications (e.g., diabetic retinopathy, neuropathy, nephropathy, diabetic foot, cardiovascular disease, and albuminuria). Statistical analyses were performed using Stata 14 (Stata Corp., College Station, TX, USA).

3 Results

3.1 Study selection

From 870 articles initially identified, 819 were excluded after the initial screening because they were duplicates or irrelevant. After a full-text review of the remaining 51 articles, two were excluded because they provided duplicate data, three because of missing data, and eight because they were not a case-control study, leaving 38 studies for analysis [[46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83]] (Fig. 1 and Table 1). The risk of bias was low in 33 studies [46,47,[49], [50], [51], [52], [53], [54], [55], [56], [57], [58],[60], [61], [62], [63], [64], [65],[67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81]] and moderate in the remaining five [48,59,66,82,83] (Table 2). The initial level of certainty was considered low in all studies, given their cross-sectional design (rating 2).Fig. 1 PRISMA 2020 flow diagram.

Fig. 1

Table 1 Characteristics of the studies reporting ischemia-modified albumin concentrations in patients with diabetes and healthy controls.

Table 1Study	Healthy controls	Patients with diabetes	Type of diabetes	
n	Age (Years)	M/F	IMA (Mean ± SD)	n	Age (Years)	M/F	IMA (Mean ± SD)	
Piwowar A et al., 2008, Poland [46]	25	57	6/19	0.33 ± 0.09^	76	65	11/65	0.56 ± 0.11^	T2DM	
Ukinc K et al., 2009, Turkey [47]	30	51	15/15	0.26 ± 0.04^	50	52	22/28	0.33 ± 0.05^	T2DM	
Dahiya K et al., 2010, India [48]	30	matched	matched	54.60 ± 15.17^	60	matched	matched	61.20 ± 21.80^	T2DM	
Kaefer M et al., 2011, Brazil [49]	26	52	7/18	0.41 ± 0.09^	80	59	31/49	0.53 ± 0.12^	T2DM	
Ma SG et al. (a) 2011, China [50]	45	56	21/24	97.35 ± 5.25^	50	56	22/28	103.30 ± 7.43^	T2DM	
Ma SG et al. (b) 2011, China [50]	45	56	21/24	97.35 ± 5.25^	47	58	19/28	139.80 ± 20.00^	T2DM	
Turk A et al. (a) 2011, Turkey [51]	36	NR	17/19	0.62 ± 0.04^	35	56	13/22	0.66 ± 0.13^	T2DM	
Turk A et al. (b) 2011, Turkey [51]	36	NR	17/19	0.62 ± 0.04^	35	60	15/20	0.77 ± 0.07^	T2DM	
Ma SG et al. (a) 2012, China [52]	33	52	23/10	46.31 ± 11.42^	56	53	36/20	61.47 ± 10.93^	T2DM	
Ma SG et al. (b) 2012, China [52]	33	52	23/10	46.31 ± 11.42^	48	54	36/12	78.15 ± 15.39^	T2DM	
Ma SG et al. (a) 2012, China [53]	40	49	16/24	43.48 ± 10.67^	30	49	12/18	60.82 ± 17.41^	T1DM	
Ma SG et al. (b) 2012, China [53]	40	49	16/24	43.48 ± 10.67^	27	47	11/16	96.22 ± 20.45^	T1DM	
Ma SG et al., 2012, China [54]	30	24	0/30	65.84 ± 10.36^	40	29	0/40	83.77 ± 11.45^	GDM	
Dayanand CD et al., 2013, India [55]	70	NR	NR	0.07 ± 0.07^	70	NR	NR	0.30 ± 0.13^	T2DM	
Korkmaz GG et al. (a) 2013, Turkey [56]	35	55	15/20	8.10 ± 0.91^	55	55	25/30	9.11 ± 0.65^	Pre-diabetes	
Korkmaz GG et al. (b) 2013, Turkey [56]	35	55	15/20	8.10 ± 0.91^	20	60	11/9	9.39 ± 0.95^	T2DM	
Kirboga K et al., 2014, Turkey [58]	22	66	matched	39.20 ± 28.80#	22	66	matched	55.30 ± 26.80#	T2DM	
Refaat G et al. (a) 2014, Egypt [59]	10	55	5/5	0.39 ± 0.10^	20	52	12/8	0.51 ± 0.21^	T2DM	
Refaat G et al. (b) 2014, Egypt [59]	10	55	5/5	0.39 ± 0.10^	20	53	11/9	0.65 ± 0.09^	T2DM	
Erdem SS et al. (a) 2015, Turkey [57]	24	44	7/17	0.54 ± 0.16^	29	44	9/30	0.59 ± 0.11^	Pre-diabetes	
Erdem SS et al. (b) 2015, Turkey [57]	24	44	7/17	0.54 ± 0.16^	30	47	11/29	0.69 ± 0.22^	T2DM	
Reddy VS et al. (a) 2015, India [60]	23	31	NR	0.30 ± 0.17^	16	64	NR	0.43 ± 0.19^	T2DM	
Reddy VS et al. (b) 2015, India [60]	23	31	matched	0.30 ± 0.17^	18	57	matched	0.57 ± 0.12^	T2DM	
Ahamad A et al. (a) 2016, India [61]	30	47	16/14	45.70 ± 23.90#	20	48	12/8	109.40 ± 50.30#	T2DM	
Ahamad A et al. (b) 2016, India [61]	30	47	16/14	45.70 ± 23.90#	20	50	12/8	154.50 ± 43.10#	T2DM	
Ahamad A et al. (c) 2016, India [61]	30	47	16/14	45.70 ± 23.90#	20	50	9/11	178.10 ± 67.90#	T2DM	
D'Souza JMP et al. (a) 2016, India [62]	50	49	matched	0.42 ± 0.12^	50	51	matched	0.52 ± 0.14^	T2DM	
D'Souza JMP et al. (b) 2016, India [62]	50	49	matched	0.42 ± 0.12^	50	53	matched	0.60 ± 0.17^	T2DM	
Inci A et al., 2016, Turkey [63]	32	50	12/20	0.45 ± 0.06^	109	62	62/47	0.47 ± 0.07^	T2DM	
Miric DJ et al. (a) 2016, Serbia [64]	30	60	13/17	28.50 ± 8.70^	51	62	20/31	34.70 ± 12.40^	T2DM	
Miric DJ et al. (b) 2016, Serbia [64]	30	60	13/17	28.50 ± 8.70^	29	63	13/16	40.30 ± 11.80^	T2DM	
Muhtaroğlu S et al. (a) 2016, Turkey [65]	30	53	16/14	0.39 ± 0.05^	30	57	15/15	0.48 ± 0.09^	T2DM	
Muhtaroğlu S et al. (b) 2016, Turkey [65]	30	53	16/14	0.39 ± 0.05^	30	59	17/13	0.72 ± 0.12^	T2DM	
Ghosh K et al., 2017, India [66]	30	NR	NR	0.30 ± 0.05^	100	56	57/43	0.58 ± 0.09^	T2DM	
Sadik L et al., 2017, Sudan [67]	70	59	30/40	3.21 ± 10.73#	70	58	30/40	10.78 ± 10.25#	T2DM	
Balamir I et al., 2018, Turkey [68]	88	53	33/55	0.46 ± 0.11^	88	55	30/58	0.55 ± 0.13^	T2DM	
Bhaskhar KU et al., 2018, India [69]	40	matched	matched	0.66 ± 0.15^	40	matched	matched	1.15 ± 0.14^	T2DM	
Sudha K et al. (a) 2018, India [70]	30	49	NR	0.86 ± 0.31^	30	52	NR	0.92 ± 0.33^	T2DM	
Sudha K et al. (b) 2018, India [70]	30	49	NR	0.86 ± 0.31^	30	47	NR	0.66 ± 0.21^	T2DM	
Yazici MU et al., 2019, Turkey [71]	30	8.9	15/15	0.59 ± 0.10^	24	10.4	11/13	0.61 ± 0.10^	T1DM	
Beyazit F et al., 2020, Turkey [72]	45	28	NR	0.01 ± 0.05^	45	31	NR	0.44 ± 0.08^	GDM	
El-Eshmawy MM et al., 2020, Egypt [73]	50	43	25/25	0.16 ± 0.01^	100	41	50/50	1.04 ± 0.01^	Pre-diabetes	
Sushith S et al. (a) 2020, India [74]	35	49	NR	0.23 ± 0.03^	35	54	NR	0.48 ± 0.69^	T2DM	
Sushith S et al. (b) 2020, India [74]	35	49	NR	0.23 ± 0.03^	35	55	NR	0.59 ± 0.51^	T2DM	
Alay H et al. (a) 2021, Turkey [75]	30	63	17/13	16.90 ± 5.30#	30	63	17/13	28.10 ± 5.40#	T2DM	
Alay H et al. (b) 2021, Turkey [75]	30	63	17/13	16.90 ± 5.30#	30	63	19/11	35.15 ± 7.70#	T2DM	
Chaudhry SR et al. (a) 2021, Pakistan [76]	20	NR	NR	0.49 ± 0.09^	20	NR	NR	0.58 ± 0.06^	T2DM	
Chaudhry SR et al. (b) 2021, Pakistan [76]	20	NR	NR	0.49 ± 0.09^	20	NR	NR	0.64 ± 0.01^	T2DM	
Mertoglu C et al. (a) 2021, Turkey [77]	50	55	NR	0.80 ± 0.30*	21	56	NR	0.50 ± 0.10*	T2DM	
Mertoglu C et al. (b) 2021, Turkey [77]	50	55	NR	0.80 ± 0.30*	22	61	NR	0.80 ± 0.40*	T2DM	
Mertoglu C et al. (c) 2021, Turkey [77]	50	55	NR	0.80 ± 0.30*	69	65	NR	1.20 ± 0.20*	T2DM	
Mertoglu C et al. (d) 2021, Turkey [77]	50	55	NR	0.80 ± 0.30*	126	58	NR	1.10 ± 0.30*	T2DM	
Ozkan S et al., 2021, Turkey [78]	60	43	30/30	1.14 ± 0.02^	120	43	75/45	2.61 ± 0.26^	T2DM	
Xiang L et al. (a) 2021, China [79]	45	54	23/22	20.11 ± 4.69#	61	54	31/30	95.41 ± 5.63#	T2DM	
Xiang L et al. (b) 2021, China [79]	45	54	23/22	20.11 ± 4.69#	34	54	18/16	77.95 ± 3.81#	T2DM	
Arslan A et al., 2022, Turkey [80]	37	27	0/37	0.86 ± 0.09^	40	27	0/40	1.53 ± 0.41^	GDM	
Feng F et al., 2022, China [81]	110	59	61/49	60.32 ± 12.70^	110	58	59/51	90.87 ± 19.43^	T2DM	
Kurt HA et al., 2022, Turkey [82]	40	55	40/0	0.26 ± 0.05^	46	52	46/0	0.35 ± 0.04^	T2DM	
Zainal IG et al., 2022, Iraq [83]	32	NR	NR	0.68 ± 0.04^	28	NR	NR	0.85 ± 0.10^	T2DM	
Legend: M/F, male to female ratio; IMA, ischemia-modified albumin; NR, not reported; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; GDM, gestational diabetes mellitus; ^, albumin cobalt binding test; #, enzyme-linked immunosorbent assay; *, analytical method not reported. IMA values are reported as absorbance units, ng/mL, or U/L.

Table 2 Assessment of the risk of bias using the Joanna Briggs Institute critical appraisal checklist.

Table 2Study	Were the inclusion criteria clearly defined?	Were the subjects and the setting described in detail?	Was the exposure measured in a reliable way?	Were standard criteria used to assess the condition?	Were confounding factors identified?	Were strategies to deal with confounding factors stated?	Were the outcomes measured in a reliable way?	Was appropriate statistical analysis used?	Risk of bias	
Piwowar A et al. [46]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Ukinc K et al. [47]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Dahiya K et al. [48]	No	No	Yes	Yes	No	No	Yes	Yes	Moderate	
Kaefer M et al. [49]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Ma SG et al. [50]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Turk A et al. [51]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Ma SG et al. [52]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Ma SG et al. [53]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Ma SG et al. [54]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Dayanand CD et al. [55]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Korkmaz GG et al. [56]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Kirboga K et al. [58]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Refaat G et al. [59]	No	No	Yes	Yes	No	No	Yes	Yes	Moderate	
Erdem SS et al. [57]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Reddy VS et al. [60]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Ahamad A et al. [61]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
D'Souza JMP et al. [62]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Inci A et al. [63]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Miric DJ et al. [64]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Muhtaroğlu S et al. [65]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Ghosh K et al. [66]	No	No	Yes	Yes	No	No	Yes	Yes	Moderate	
Sadik L et al. [67]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Balamir I et al. [68]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Bhaskhar KU et al. [69]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Sudha K et al. [70]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Yazici MU et al. [71]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Beyazit F et al. [72]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
El-Eshmawy MM et al. [73]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Sushith S et al. [74]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Alay H et al. [75]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Chaudhry SR et al. [76]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Mertoglu C et al. [77]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Ozkan S et al. [78]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Xiang L et al. [79]	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low	
Arslan A et al. [80]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Feng F et al. [81]	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Low	
Kurt HA et al. [82]	No	No	Yes	Yes	No	No	Yes	Yes	Moderate	
Zainal IG et al. [83]	No	No	Yes	Yes	No	No	Yes	Yes	Moderate	

3.2 Ischemia-modified albumin and type 2 diabetes mellitus

Twenty-nine studies, including 47 group comparisons, investigated serum IMA in 2143 T2DM patients (mean age 56 years, 52 % females) and 1706 healthy controls (mean age 52 years, 53 % females) [[46], [47], [48], [49], [50], [51], [52],[55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70],[74], [75], [76], [77], [78], [79]]. Eleven studies were conducted in Turkey [47,51,[56], [57], [58],63,65,68,75,77,78], nine in India [48,55,[60], [61], [62],66,69,70,74], three in China [50,52,79], one in Serbia [64], one in Poland [46], one in Brazil [49], one in Egypt [59], one in Sudan [67], and one in Pakistan [76]. Five studies measured IMA using an enzyme-linked immunosorbent assay (ELISA) [58,61,67,75,79], 23 an albumin cobalt binding (ACB) test [[46], [47], [48], [49], [50], [51], [52],[55], [56], [57],59,60,[62], [63], [64], [65], [66],[68], [69], [70],74,76,78], whereas the remaining one did not provide relevant information regarding the test used [77]. The mean T2DM disease duration ranged between 0 and 15 years.

The forest plot showed that serum IMA concentrations were significantly higher in T2DM patients when compared to controls (SMD = 1.83, 95 % CI 1.46 to 2.21, p˂0.001; I2 = 95.7 %, p < 0.001; Fig. 2). Sensitivity analysis confirmed the stability of the meta-analysis results, with the corresponding pooled SMD values ranging between 1.64 and 1.69 (Fig. 3). However, the last three group comparisons [78,79] exerted a slightly distortive effect on the effect size, and therefore, their combined omission should be considered to evaluate the effect on the SMD. This is also evident in the funnel plot analysis, which confirmed the distortive effect of the three group comparisons [78,79] (enclosed circles in Fig. 4). Their removal reduced the magnitude of the effect size, which, however, remained significant (SMD = 1.37, 95 % CI 1.08 to 1.65, p˂0.001; I2 = 92.5 %, p < 0.001).Fig. 2 Forest plot of studies investigating serum ischemia-modified albumin concentrations in patients with type 2 diabetes and healthy controls.

Fig. 2

Fig. 3 Sensitivity analysis of the association between serum ischemia-modified albumin and type 2 diabetes.

Fig. 3

Fig. 4 Funnel plot of studies investigating the association between serum ischemia-modified albumin and type 2 diabetes.

Fig. 4

The analysis of small studies' effect on the remaining 44 study groups showed significant publication bias according to Begg's (p = 0.001) and Egger's (p = 0.001) test. Accordingly, the “trim-and-fill” method identified nine missing studies to be added to the left side of the funnel plot to ensure symmetry (Fig. 5). The effect size was further reduced to 0.95 (95 % CI 1.08 to 1.65, p˂0.001) but remained significant.Fig. 5 Funnel plot of studies investigating the association between serum ischemia-modified albumin and type 2 diabetes after “trimming and filling”. Dummy studies and genuine studies are represented by enclosed circles and free circles, respectively.

Fig. 5

In meta-regression analysis, there were no significant associations between the effect size and age (t = −0.08, p = 0.940), male to female ratio (t = −0.53, p = 0.600), participant number (t = −0.42, p = 0.676), publication year (t = −0.89, p = 0.381), mean disease duration (t = 1.33, p = 0.194), BMI (t = −1.48, p = 0.156), CRP (t = 1.46, p = 0.178), albumin (t = −1.26, p = 0.223), total cholesterol (t = 0.31, p = 0.759), LDL-cholesterol (t = −0.56, p = 0.581), HDL-cholesterol (t = −0.98, p = 0.341), systolic (t = 0.70, p = 0.496), or diastolic pressure (t = 0.14, p = 0.894). By contrast, significant and positive associations were observed between the effect size and glycated hemoglobin (t = 2.87, p = 0.007), creatinine (t = 2.35, p = 0.003), and triglycerides (t = 2.35, p = 0.029) (Fig. 6). In addition, a non-significant trend was observed with serum glucose (t = 1.74, p = 0.092).Fig. 6 Bubble plot reporting univariate meta-regression analysis between the effect size and glycated haemoglobin (A), creatinine (B), and triglycerides (C).

Fig. 6

In subgroup analysis, the pooled SMD was statistically significant in studies conducted in Turkey (SMD = 1.49, 95 % CI 0.86 to 2.11, p˂0.001; I2 = 96.2 %, p˂0.001), India (SMD = 1.48, 95 % CI 0.88 to 2.08, p˂0.001; I2 = 94.6 %, p˂0.001), China (SMD = 5.45, 95 % CI 3.40 to 7.50, p˂0.001; I2 = 98.3 %, p˂0.001), and other countries (SMD = 1.33, 95 % CI 0.87 to 1.80, p˂0.001; I2 = 83.1 %, p˂0.001, Fig. 7). The effect size in Chinese studies was significantly higher when compared to other countries (p = 0.001). In addition, a significant difference (p = 0.006) was observed between the pooled SMD of studies using ACB (SMD = 1.53, 95 % CI 1.15 to 1.91, p˂0.001; I2 = 94.5 %, p˂0.001) and ELISA (SMD = 4.30, 95 % CI 1.58 to 2.38, p˂0.001; I2 = 97.7 %, p˂0.001, Fig. 8). Finally, there was a significant difference (p = 0.003) in the pooled SMD between studies conducted in T2DM patients with complications (SMD = 1.94, 95 % CI 1.46 to 2.43, p˂0.001; I2 = 92.6 %, p˂0.001) and without complications (SMD = 0.85, 95 % CI 0.50 to 1.19, p˂0.001; I2 = 86.0 %, p˂0.001, Fig. 9). The reported complications included diabetic retinopathy, neuropathy, nephropathy, diabetic foot, cardiovascular disease, and albuminuria [46,[50], [51], [52],58,[60], [61], [62], [63], [64], [65],69,[75], [76], [77]].Fig. 7 Forest plot of studies investigating serum ischemia-modified albumin concentrations in patients with type 2 diabetes and healthy controls according to the study country.

Fig. 7

Fig. 8 Forest plot of studies investigating serum ischemia-modified albumin concentrations in patients with type 2 diabetes and healthy controls according to the assay used to detect ischemia-modified albumin.

Fig. 8

Fig. 9 Forest plot of studies investigating serum ischemia-modified albumin concentrations in patients with type 2 diabetes and healthy controls according to the presence of diabetic complications.

Fig. 9

The overall level of certainty remained low (rating 2) after considering the low-moderate risk of bias in all studies (no change), the high and unexplainable heterogeneity (downgrade one level), the lack of indirectness (no change), the large effect size (SMD = 1.83, upgrade one level) [84], and the presence of publication bias which was partially addressed by the “trim and fill” method (no change).

3.3 Ischemia-modified albumin and type 1 diabetes mellitus

Two studies with three group comparisons investigated serum IMA in a total of 81 T1DM patients (mean age 37 years, 58 % females) and 110 healthy controls (mean age 38 years, 57 % females) [53,71]. One study was conducted in Turkey [71], and one in China [53], and both used the ACB assay to measure serum IMA.

The forest plot showed that IMA concentrations were non-significantly higher in T1DM patients when compared to controls (SMD = 1.59, 95 % CI -0.09 to 3.26, p˂0.063; I2 = 95.8 %, p < 0.001; Fig. 10).Fig. 10 Forest plot of studies investigating serum ischemia-modified albumin concentrations in patients with type 1 diabetes and healthy controls.

Fig. 10

Because of the small number of studies, sensitivity, publication bias, meta-regression, and sub-group analyses could not be assessed. Consequently, the certainty of evidence was downgraded to very low (rating 1).

3.4 Ischemia-modified albumin and gestational diabetes mellitus

Three studies investigated serum IMA in 125 patients with GDM (mean age 29 years) and 112 healthy controls (mean age 27 years) [54,72,80]. Two studies were conducted in Turkey [72,80], and one in China [54], and all used the ACB assay to measure serum IMA.

The forest plot showed that serum IMA concentrations were significantly higher in patients with GDM when compared to controls (SMD = 3.41, 95 % CI 1.14 to 5.67, p = 0.003; I2 = 97.0 %, p < 0.001; Fig. 11).Fig. 11 Forest plot of studies investigating serum ischemia-modified albumin concentrations in patients with gestational diabetes mellitus and healthy controls.

Fig. 11

Because of the small number of studies, sensitivity, publication bias, meta-regression, and sub-group analyses could not be assessed. Consequently, the certainty of evidence was downgraded to very low (rating 1).

3.5 Ischemia-modified albumin and pre-diabetes

Three studies investigated serum IMA in 184 patients with pre-diabetes (mean age 46 years, 57 % females) and 109 healthy controls (mean age 47 years, 57 % females) [56,57,73]. Two studies were performed in Turkey [56,57], one in Egypt [73], and all used the ACB assay to measure serum IMA.

The forest plot showed that serum IMA concentrations were significantly higher in patients with pre-diabetes than controls (SMD = 15.25, 95 % CI 9.86 to 20.65, p˂0.001; I2 = 99.3 %, p < 0.001; Fig. 12).Fig. 12 Forest plot of studies investigating serum ischemia-modified albumin concentrations in patients with pre-diabetes and healthy controls.

Fig. 12

Because of the small number of studies, sensitivity, publication bias, meta-regression, and sub-group analyses could not be assessed. Consequently, the certainty of evidence was downgraded to very low (rating 1).

4 Discussion

A significant proportion of the articles captured in our systematic literature search involved patients with TD2M. Our analyses showed that T2DM patients had significantly higher IMA concentrations when compared to healthy controls. In meta-regression and subgroup analysis, significant associations were observed between the effect size and glycated hemoglobin, creatinine, triglycerides, and the presence of diabetes complications. Another interesting finding in subgroup analysis was that the SMD was significantly different in studies of different geographical location, which supports the generalizability of our findings. Similar observations of higher IMA concentrations, albeit in a smaller number of studies, were observed in patients with T1DM, GDM, and pre-diabetes. Collectively, these results suggest the potential role of IMA as a biomarker of oxidative stress, acidosis, and ischemia in different types of diabetes as well as pre-diabetes.

Although the exact chemical reactions involved in forming IMA are not fully established, IMA generally reverts to albumin following an ischaemic event. For example, a balloon occlusion during a percutaneous coronary intervention was shown to increase serum IMA concentrations acutely. This increase persisted for up to 12 h before returning to baseline after a further 12 h [85]. It has been suggested that the magnitude of the formation of IMA is positively associated with the duration of the ischaemic process [25].

Several methods have been developed to measure IMA. Whilst some are relatively simple and have high sensitivity and specificity, particularly the ACB assay, the ELISA, and the surface plasmon resonance immunosensor, their use is currently limited to research studies [25]. In our systematic review and meta-analysis, most of the selected studies used the ABC method based on measuring the binding of cobalt to albumin in serum [86]. Whilst extensively used, this method is not exempt from limitations as conformational changes in albumin due to fluctuations in pH or the presence of denaturing agents, chemicals, or medications can influence the results [25]. Another issue is the lack of standardization, as most authors express the results as absorbance units, which might depend on the experience of the investigator and/or the sensitivity of the equipment [25]. Furthermore, some investigators have used IMA internal standards obtained in their laboratories [25]. Such limitations might explain, at least partly, the between-study variance in our meta-analysis. However, the lack of consensus regarding the exact mechanisms involved in the formation of IMA should also be emphasized. To address these issues, methods based on immunological reactions using antibodies to modified albumin have been proposed, although their use remains relatively limited. In our analyses, the use of ELISA was associated with a significantly larger effect size when compared to ACB spectrophotometric assays.

The role of IMA as a biomarker has been traditionally investigated in clinically overt ischaemic states, e.g., acute coronary syndrome and ischemic stroke. However, a significant increase in IMA concentrations has also been reported in heart failure [87], neurodegenerative disorders [88], pregnancy disorders [89], and cancer [90]. The results of these studies suggest that the likely common denominator for the acute increase in IMA accompanying a wide range of conditions is a state of oxidative stress and, perhaps, acidosis, rather than ischemia per se [91,92]. This hypothesis is further corroborated by a study investigating IMA as a biomarker of lower-extremity artery disease, a condition characterized by a significant pro-inflammatory and pro-oxidant state in T2DM patients. In this study, IMA concentrations were independently associated with the risk of peripheral revascularization or lower-limb amputation after 5.6 years of follow-up [93]. Appropriately designed prospective studies are warranted to investigate the capacity of IMA to predict diabetes complications and other adverse clinical outcomes in order to justify the use of this biomarker in routine practice.

Strengths of our study include the assessment of serum IMA in pre-diabetes and different types of diabetes, i.e., T2DM, T1DM, and GDM, the assessment of possible associations between the effect size and several study and patient characteristics (only possible for T2DM because of the sufficient number of studies), and a rigorous evaluation of the risk of bias and the certainty of evidence. Furthermore, sensitivity analysis ruled out the effect of individual studies on the overall effect size. Important limitations include the lack of assessment of publication bias and the assessment of meta-regression and subgroup analysis in studies of T1DM, GDM, and pre-diabetes because of the limited number of studies identified. Furthermore, it is important to highlight that all the identified studies were cross-sectional. This study design does not allow establishing a cause-effect relationship between serum IMA concentrations and pre-diabetes or different types of diabetes. As previously discussed, longitudinal studies are now required to appropriately investigate whether alterations in IMA can causally lead to alterations in glycaemic control and specific clinical complications. Only then, can the role of IMA as a biomarker of diabetes be fully established.

5 Conclusion

In conclusion, our systematic review and meta-analysis has shown the potential utility of serum IMA as a biomarker of pre-diabetes and T2DM, T1DM, and GDM and of diabetes complications in T2DM patients. However, additional research is required to confirm these observations and determine whether IMA can enhance risk stratification and the capacity to predict diabetes complications and other adverse clinical outcomes in prospective studies in order to justify its routine use in clinical practice.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability

The data that support the findings of this systematic review and meta-analysis are available from AZ upon reasonable request.

CRediT authorship contribution statement

Angelo Zinellu: Writing – review & editing, Methodology, Formal analysis, Data curation, Conceptualization. Arduino A. Mangoni: Writing – review & editing, Writing – original draft, Validation, Methodology, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A Supplementary data

The following are the Supplementary data to this article:Multimedia component 1

Multimedia component 1

Multimedia component 2

Multimedia component 2

Acknowledgements

None.

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e35953.
==== Refs
References

1 Lin X. Xu Y. Pan X. Xu J. Ding Y. Sun X. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025 Sci. Rep. 10 1 2020 14790
2 Khan M.A.B. Hashim M.J. King J.K. Govender R.D. Mustafa H. Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends J Epidemiol Glob Health 10 1 2020 107 111 32175717
3 Collaborators G.B.D.D. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 Lancet 402 10397 2023 203 234 37356446
4 Guo S.J. Shao H. Growing global burden of type 1 diabetes needs multitiered precision public health interventions Lancet Diabetes Endocrinol. 10 10 2022 688 689 36113506
5 Gregory G.A. Robinson T.I.G. Linklater S.E. Wang F. Colagiuri S. de Beaufort C. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study Lancet Diabetes Endocrinol. 10 10 2022 741 760 36113507
6 Mnatzaganian G. Woodward M. McIntyre H.D. Ma L. Yuen N. He F. Trends in percentages of gestational diabetes mellitus attributable to overweight, obesity, and morbid obesity in regional Victoria: an eight-year population-based panel study BMC Pregnancy Childbirth 22 1 2022 95 35105311
7 Bahl S. Dhabhai N. Taneja S. Mittal P. Dewan R. Kaur J. Burden, risk factors and outcomes associated with gestational diabetes in a population-based cohort of pregnant women from North India BMC Pregnancy Childbirth 22 1 2022 32 35031013
8 Laurie J.G. McIntyre H.D. A review of the current status of gestational diabetes mellitus in Australia-the clinical impact of changing population demographics and diagnostic criteria on prevalence Int J Environ Res Public Health 17 24 2020
9 Rooney M.R. Fang M. Ogurtsova K. Ozkan B. Echouffo-Tcheugui J.B. Boyko E.J. Global prevalence of prediabetes Diabetes Care 46 7 2023 1388 1394 37196350
10 Echouffo-Tcheugui J.B. Kengne A.P. Ali M.K. Issues in defining the burden of prediabetes globally Curr Diab Rep 18 11 2018 105 30229351
11 Hostalek U. Global epidemiology of prediabetes - present and future perspectives Clin Diabetes Endocrinol 5 2019 5 31086677
12 Sattar N. Advances in the clinical management of type 2 diabetes: a brief history of the past 15 years and challenges for the future BMC Med. 17 1 2019 46 30803451
13 Su J. Luo Y. Hu S. Tang L. Ouyang S. Advances in research on type 2 diabetes mellitus targets and therapeutic agents Int. J. Mol. Sci. 24 17 2023
14 Aathira R. Jain V. Advances in management of type 1 diabetes mellitus World J. Diabetes 5 5 2014 689 696 25317246
15 Akil A.A. Yassin E. Al-Maraghi A. Aliyev E. Al-Malki K. Fakhro K.A. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era J. Transl. Med. 19 1 2021 137 33794915
16 Benhalima K. Recent advances in gestational diabetes mellitus J. Clin. Med. 10 10 2021
17 Bukhari I. Iqbal F. Thorne R.F. Research advances in gestational, neonatal diabetes mellitus and metabolic disorders Front. Endocrinol. 13 2022 969952
18 Echouffo-Tcheugui J.B. Perreault L. Ji L. Dagogo-Jack S. Diagnosis and management of prediabetes: a review JAMA 329 14 2023 1206 1216 37039787
19 Lyons T.J. Basu A. Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers Transl. Res. 159 4 2012 303 312 22424433
20 Sherwani S.I. Khan H.A. Ekhzaimy A. Masood A. Sakharkar M.K. Significance of HbA1c test in diagnosis and prognosis of diabetic patients Biomark. Insights 11 2016 95 104 27398023
21 Sonaglioni A. Bordoni T. Naselli A. Nicolosi G.L. Grasso E. Bianchi S. Influence of gestational diabetes mellitus on subclinical myocardial dysfunction during pregnancy: a systematic review and meta-analysis Eur. J. Obstet. Gynecol. Reprod. Biol. 292 2024 17 24 37951113
22 Dorcely B. Katz K. Jagannathan R. Chiang S.S. Oluwadare B. Goldberg I.J. Novel biomarkers for prediabetes, diabetes, and associated complications Diabetes Metab Syndr Obes 10 2017 345 361 28860833
23 Ortiz-Martinez M. Gonzalez-Gonzalez M. Martagon A.J. Hlavinka V. Willson R.C. Rito-Palomares M. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus Curr Diab Rep 22 3 2022 95 115 35267140
24 Laakso M. Biomarkers for type 2 diabetes Mol Metab 27S Suppl 2019 S139 S146 31500825
25 Shevtsova A. Gordiienko I. Tkachenko V. Ushakova G. Ischemia-modified albumin: origins and clinical implications Dis. Markers 2021 2021 9945424
26 Abboud H. Labreuche J. Meseguer E. Lavallee P.C. Simon O. Olivot J.M. Ischemia-modified albumin in acute stroke Cerebrovasc. Dis. 23 2–3 2007 216 220 17143006
27 Jawade P. Khillare K.M. Mangudkar S. Palange A. Dhadwad J. Deshmukh M. A comparative study of ischemia-modified albumin: a promising biomarker for early detection of acute coronary syndrome (ACS) Cureus 15 8 2023 e44357
28 Gaze D.C. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia Drug Metab Pharmacokinet 24 4 2009 333 341 19745560
29 Worster A. Devereaux P.J. Heels-Ansdell D. Guyatt G.H. Opie J. Mookadam F. Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome CMAJ (Can. Med. Assoc. J.) 172 13 2005 1685 1690 15967971
30 Ighodaro O.M. Molecular pathways associated with oxidative stress in diabetes mellitus Biomed. Pharmacother. 108 2018 656 662 30245465
31 Zhang P. Li T. Wu X. Nice E.C. Huang C. Zhang Y. Oxidative stress and diabetes: antioxidative strategies Front. Med. 14 5 2020 583 600 32248333
32 An Y. Xu B.T. Wan S.R. Ma X.M. Long Y. Xu Y. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction Cardiovasc. Diabetol. 22 1 2023 237 37660030
33 Giha H.A. Hidden chronic metabolic acidosis of diabetes type 2 (CMAD): clues, causes and consequences Rev. Endocr. Metab. Disord. 24 4 2023 735 750 37380824
34 Souto G. Donapetry C. Calvino J. Adeva M.M. Metabolic acidosis-induced insulin resistance and cardiovascular risk Metab. Syndr. Relat. Disord. 9 4 2011 247 253 21352078
35 Nellaiappan K. Preeti K. Khatri D.K. Singh S.B. Diabetic complications: an update on pathobiology and therapeutic strategies Curr. Diabetes Rev. 18 1 2022 e030821192146
36 Moola S. Munn Z. Tufanaru C. Aromataris E. Sears K. Sfetcu R. Systematic reviews of etiology and risk Aromataris E. Munn Z. Joanna Briggs Institute Reviewer's Manual 2017 Johanna Briggs Institute Adelaide, Australia
37 Balshem H. Helfand M. Schunemann H.J. Oxman A.D. Kunz R. Brozek J. GRADE guidelines: 3. Rating the quality of evidence J. Clin. Epidemiol. 64 4 2011 401 406 21208779
38 Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 372 2021 n71
39 Wan X. Wang W. Liu J. Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range BMC Med. Res. Methodol. 14 2014 135 25524443
40 Higgins J.P. Thompson S.G. Quantifying heterogeneity in a meta-analysis Stat. Med. 21 11 2002 1539 1558 12111919
41 Higgins J.P. Thompson S.G. Deeks J.J. Altman D.G. Measuring inconsistency in meta-analyses BMJ 327 7414 2003 557 560 12958120
42 Tobias A. Assessing the influence of a single study in the meta-analysis estimate Stata Technical Bulletin 47 1999 15 17
43 Begg C.B. Mazumdar M. Operating characteristics of a rank correlation test for publication bias Biometrics 50 4 1994 1088 1101 7786990
44 Sterne J.A. Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis J. Clin. Epidemiol. 54 10 2001 1046 1055 11576817
45 Duval S. Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2 2000 455 463 10877304
46 Piwowar A. Knapik-Kordecka M. Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - preliminary report Dis. Markers 24 6 2008 311 317 18688079
47 Ukinc K. Eminagaoglu S. Ersoz H.O. Erem C. Karahan C. Hacihasanoglu A.B. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin Endocrine 36 3 2009 425 432 19784800
48 Dahiya K. Aggarwal K. Seth S. Singh V. Sharma T.K. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin Clin. Lab. 56 5–6 2010 187 190 20575465
49 Kaefer M. Piva S.J. De Carvalho J.A. Da Silva D.B. Becker A.M. Coelho A.C. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus Clin. Biochem. 43 4–5 2010 450 454 19968982
50 Ma S.G. Xu W. Wei C.L. Wu X.J. Hong B. Wang Z.J. Role of ischemia-modified albumin and total homocysteine in estimating symptomatic lacunar infarction in type 2 diabetic patients Clin. Biochem. 44 16 2011 1299 1303 21906585
51 Turk A. Nuhoglu I. Mentese A. Karahan S.C. Erdol H. Erem C. The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde Retina 31 3 2011 602 608 21273947
52 Ma S.G. Jin Y. Hu W. Bai F. Xu W. Yu W.N. Evaluation of ischemia-modified albumin and C-reactive protein in type 2 diabetics with and without ketosis Biomark. Insights 7 2012 19 26 22442627
53 Ma S.G. Jin Y. Xu W. Hu W. Bai F. Wu X.J. Increased serum levels of ischemia-modified albumin and C-reactive protein in type 1 diabetes patients with ketoacidosis Endocrine 42 3 2012 570 576 22437883
54 Ma S.G. Yu W.N. Jin Y. Hong B. Hu W. Evaluation of serum ischemia-modified albumin levels in pregnant women with and without gestational diabetes mellitus Gynecol. Endocrinol. 28 11 2012 837 840 22571721
55 Dayanand C.D. Vegi P.K. Lakshmaiah V. Kutty A.V.M. Association of ischemia modified albumin in terms of hypoxic risk with carbonylated protein, glycosylated hemoglobin and plasma insulin in type 2 diabetes mellitus Int. J. Biotechnol. Biochem. 9 3 2013 275 284
56 Korkmaz G.G. Konukoglu D. Kurtulus E.M. Irmak H. Bolayirli M. Uzun H. Total antioxidant status and markers of oxidative stress in subjects with normal or impaired glucose regulation (IFG, IGT) in diabetic patients Scand. J. Clin. Lab. Invest. 73 8 2013 641 649 24152132
57 Erdem S.S. Toker A. Kayrak M. Çiçekler H. Gönülalan G. Abdulhalikov T. Oxidant and antioxidant parameters in prediabetes and diabetes Int. J. Diabetes Dev. Ctries. 35 S3 2014 465 470
58 Kirboga K. Ozec A.V. Kosker M. Dursun A. Toker M.I. Aydin H. The association between diabetic retinopathy and levels of ischemia-modified albumin, total thiol, total antioxidant capacity, and total oxidative stress in serum and aqueous humor J Ophthalmol 2014 2014 820853
59 Refaat S. El-Ghaffar N.A. Khalil A. The relationship between ischemia modified albumin and lipids in type 2 Egyptian diabetic patients Adv. Biol. Res. 8 1 2014 18 22
60 Reddy V.S. Agrawal P. Sethi S. Gupta N. Garg R. Madaan H. Associations of FPG, A1C and disease duration with protein markers of oxidative damage and antioxidative defense in type 2 diabetes and diabetic retinopathy Eye 29 12 2015 1585 1593 26381098
61 Ahmad A. Manjrekar P. Yadav C. Agarwal A. Srikantiah R.M. Hegde A. Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy Biomark. Insights 11 2016 63 68 27158221
62 D'Souza J.M. D'Souza R.P. Vijin V.F. Shetty A. Arunachalam C. Pai V.R. High predictive ability of glycated hemoglobin on comparison with oxidative stress markers in assessment of chronic vascular complications in type 2 diabetes mellitus Scand. J. Clin. Lab. Invest. 76 1 2016 51 57 26494020
63 Inci A. Olmaz R. Sari F. Coban M. Ellidag H.Y. Sarikaya M. Increased oxidative stress in diabetic nephropathy and its relationship with soluble Klotho levels Hippokratia 20 3 2016 198 203 29097885
64 Miric D.J. Kisic B.M. Filipovic-Danic S. Grbic R. Dragojevic I. Miric M.B. Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy J. Diabetes Res. 2016 2016 4370490
65 Muhtaroglu S. Barlak Keti D. Unluhizarci K. Investigation of ischemia-modified albumin levels and some atherosclerosis-related serum parameters in patients with diabetic foot Turk. J. Med. Sci. 46 1 2016 126 132 27511345
66 Ghosh K. Muddeshwar M.G. Ghosh K. Ischemia modified albumin test to detect early diabetic complications Am. J. Med. Sci. 354 5 2017 467 470 29173357
67 Sadik I. Yagoub Z. Sayed N. El Nour A. Abide El Hameed M. Satee A.B. The level of ischemic modified albumin (IMA) as risk marker for cardio vascular disease (CVD) among some diabetic patients (type II) in khartoum state -Sudan Sudan Journal of Medical Sciences 12 4 2017
68 Balamir I. Ates I. Topcuoglu C. Turhan T. Association of Endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus Angiology 69 7 2018 609 616 29172652
69 Bhaskhar K.U. Devİ H.N. Bitla A.R. Rao S. Kumar S.V. Sachan A.B. Ischemia modified albumin levels in patients with diabetic nephropathy The Turkish Journal of Endocrinology and Metabolism 22 3 2018 145 150
70 Sudha K. Reshma K. Ahmad A. Marathe A. Correlation of atherogenic indices and IMA with glycaemic control in diabetic patients with and without dyslipidemia Indian Journal of Public Health Research & Development 9 1 2018
71 Yazici M.U. Ayar G. Savas-Erdeve S. Azapagasi E. Neselioglu S. Erel O. Role of ischemia modified albumin serum levels as an oxidative stress marker in children with diabetic ketoacidosis Comb. Chem. High Throughput Screen. 22 8 2019 577 581 31595845
72 Beyazit F. Karacaer K.Ö. Turkon H. The association of oxidative stress with serum irisin and betatrophin in pregnant women with gestational diabetes mellitus Clin. Diabetol. 9 5 2020 328 334
73 El-Eshmawy M.M. Gad D.F. El-Baiomy A.A. Elevated serum levels of ischemia modified albumin and malondialdehyde are related to atherogenic index of plasma in a cohort of prediabetes Endocr., Metab. Immune Disord.: Drug Targets 20 8 2020 1347 1354 32359342
74 Sushith S. Krishnamurthy H.N. Reshma S. Janice D. Madan G. Ashok K.J. Serum ischemia-modified albumin, fibrinogen, high sensitivity C- reactive proteins in type-2 diabetes mellitus without hypertension and diabetes mellitus with hypertension: a case-control study Rep Biochem Mol Biol 9 2 2020 241 249 33178875
75 Alay H. Laloglu E. Kesmez Can F. An evaluation of ischemia-modified albumin levels in the development of diabetic foot ulcer Int. J. Clin. Pract. 75 9 2021 e14589
76 Chaudhry S.R. Saeed M. Chaudhry Z.R. Iqbal K. Rashid E. Rasheed F. Ischemia modified albumin levels in diabetes mellitus patients with and without diabetic retinopathy J Islam Int Med Coll 16 3 2021 161 164
77 Mertoglu C. Siranli G. Coban T.A. Karakurt Y. Ersoy A. Ozcicek A. The role of protein oxidation in the development of diabetic microvascular complications North Clin Istanb 8 5 2021 500 506 34909589
78 Ozkan S. Adanas C. Alp H.H. Is ischemia-modified albumin a biomarker in wagner classification in diabetic foot ulcers? Int. J. Clin. Pract. 75 12 2021 e14830
79 Xiang L. Zhang M. Wu H. Xie D. The expression and prognostic value of ischemia modified albumin (IMA), red blood cell distribution width (RDW), and lipoprotein (LP) in patients with diabetes mellitus complicated with coronary heart disease Ann. Palliat. Med. 10 4 2021 4463 4471 33894715
80 Arslan A. Serum ischemia modified albumin and oxidative stress levels in patients with gestational diabetes mellitus E. J. Med. 27 4 2022 507 512
81 Feng F. Chen Y. Wang G. Huang P. Zhu Q. Zhou B. Correlation of serum CysC, IMA, and LP-PLA2 levels with type 2 diabetes mellitus patients with lower extremity atherosclerotic occlusive disease Front Surg 9 2022 846470
82 Kurt H.A. Demirci E. Alan C. Endothelial dysfunction and ischemia-modified albumin levels in males with diabetic and nondiabetic erectile dysfunction Dis. Markers 2022 2022 3661822
83 Zainal I.G. Study the profile of some antioxidant markers in diabetic mellitus and non-diabetic patients with cardiovascular disease Med J Babylon 19 4 2022 653 658
84 Cohen J. Statistical power analysis Curr. Dir. Psychol. Sci. 1 3 1992 98 101
85 Sinha M.K. Vazquez J.M. Calvino R. Gaze D.C. Collinson P.O. Kaski J.C. Effects of balloon occlusion during percutaneous coronary intervention on circulating Ischemia Modified Albumin and transmyocardial lactate extraction Heart 92 12 2006 1852 1853 17105887
86 Bar-Or D. Lau E. Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report J. Emerg. Med. 19 4 2000 311 315 11074321
87 Ellidag H.Y. Eren E. Yilmaz N. Cekin Y. Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure Redox Rep. 19 3 2014 118 123 24620936
88 Altunoglu E. Guntas G. Erdenen F. Akkaya E. Topac I. Irmak H. Ischemia-modified albumin and advanced oxidation protein products as potential biomarkers of protein oxidation in Alzheimer's disease Geriatr. Gerontol. Int. 15 7 2015 872 880 25345484
89 Rossi A. Bortolotti N. Vescovo S. Romanello I. Forzano L. Londero A.P. Ischemia-modified albumin in pregnancy Eur. J. Obstet. Gynecol. Reprod. Biol. 170 2 2013 348 351 23891063
90 Kundaktepe B.P. Sozer V. Durmus S. Kocael P.C. Kundaktepe F.O. Papila C. The evaluation of oxidative stress parameters in breast and colon cancer Medicine (Baltim.) 100 11 2021 e25104
91 Liguori I. Russo G. Curcio F. Bulli G. Aran L. Della-Morte D. Oxidative stress, aging, and diseases Clin. Interv. Aging 13 2018 757 772 29731617
92 Hajam Y.A. Rani R. Ganie S.Y. Sheikh T.A. Javaid D. Qadri S.S. Oxidative stress in human pathology and aging: molecular mechanisms and perspectives Cells 11 3 2022
93 Nativel M. Schneider F. Saulnier P.J. Gand E. Ragot S. Meilhac O. Prognostic values of inflammatory and redox status biomarkers on the risk of major lower-extremity artery disease in individuals with type 2 diabetes Diabetes Care 41 10 2018 2162 2169 30072406
